InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Establishes leadership position in manufacturing and commercialization of rare cannabinoids
Positions InMed within large and growing consumer health and wellness cannabinoid markets
